Breyanzi is a cell-based immunotherapy approved for treating certain kinds of B-cell lymphoma in adults. It’s used in situations where cancer has come back after past treatment or is not responding to ...
Breyanzi is a type of cancer treatment known as CAR T-cell therapy. Common side effects include fatigue, fever, and chills. Serious side effects, such as cytokine release syndrome (CRS), are also ...
Has come back (relapsed) within a year of treatment or does not go away (refractory) after your first treatment Has relapsed or is refractory and you cannot receive a hematopoietic stem cell ...
With these data, Breyanzi demonstrates efficacy and manageable safety in a fifth cancer type, the most of any CD19-directed CAR T cell therapy PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb ...
Approval of Breyanzi is based on results from TRANSCEND WORLD, and TRANSCEND NHL 001, the largest pivotal trial of patients with relapsed or refractory large B-cell lymphoma after at least two prior ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results